Advertisement
Screener

GERON CORP (GERN) Financing Cash Flow

2.8 / 5 stars · 68/120 Roast Me

GERON CORP Financing Cash Flow

GERON CORP (GERN) reported Financing Cash Flow of $3.81 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.

Financial Statements › Cash Flow › Financing Activities

us-gaap:NetCashProvidedByUsedInFinancingActivities · last filed 2026-08-05

  • GERON CORP net cash provided by (used in) financing activities for the quarter ending 2026-06-30 was $1.38M, a 26.86% increase year-over-year.
  • GERON CORP net cash provided by (used in) financing activities for the quarter ending 2026-03-31 was $2.42M, a 847.27% increase year-over-year.
  • GERON CORP net cash provided by (used in) financing activities for the quarter ending 2025-12-31 was $378.00K, a 99.77% decline year-over-year.
  • GERON CORP net cash provided by (used in) financing activities for the quarter ending 2025-09-30 was $542.00K, a 84.85% decline year-over-year.
  • GERON CORP net cash provided by (used in) financing activities for fiscal 2025 was $2.27M, a 99.32% decline from fiscal 2024.
  • GERON CORP net cash provided by (used in) financing activities for fiscal 2024 was $334.37M, a 7.64% decline from fiscal 2023.
  • GERON CORP net cash provided by (used in) financing activities for fiscal 2023 was $362.02M, a 314.86% increase from fiscal 2022.
  • GERON CORP net cash provided by (used in) financing activities for fiscal 2022 was $87.26M, a 79.72% increase from fiscal 2021.
Period endNet Cash Provided by (Used in) Financing Activities 3 monthNet Cash Provided by (Used in) Financing Activities 6 monthNet Cash Provided by (Used in) Financing Activities 9 monthNet Cash Provided by (Used in) Financing Activities 12 month
2026-06-30$1.38M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$3.81M
10-Q · filed 2026-08-05
$4.19M
derived: sum of 3 quarters · filed 2026-08-05
$4.73M
derived: sum of 4 quarters · filed 2026-08-05
2026-03-31$2.42M
10-Q · filed 2026-05-06
$2.80M
derived: sum of 2 quarters · filed 2026-05-06
$3.35M
derived: sum of 3 quarters · filed 2026-05-06
$4.44M
derived: sum of 4 quarters · filed 2026-08-05
2025-12-31$378.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02
$920.00K
derived: sum of 2 quarters · filed 2026-03-02
$2.01M
derived: sum of 3 quarters · filed 2026-08-05
$2.27M
10-K · filed 2026-03-02
2025-09-30$542.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07
$1.63M
derived: sum of 2 quarters · filed 2026-08-05
$1.89M
10-Q · filed 2025-11-07
$168.05M
derived: sum of 4 quarters · filed 2026-08-05
2025-06-30$1.09M
derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05
$1.35M
10-Q · filed 2026-08-05
$167.51M
derived: sum of 3 quarters · filed 2026-08-05
$171.09M
derived: sum of 4 quarters · filed 2026-08-05
2025-03-31$256.00K
10-Q · filed 2026-05-06
$166.42M
derived: sum of 2 quarters · filed 2026-05-06
$170.00M
derived: sum of 3 quarters · filed 2026-05-06
$186.83M
derived: sum of 4 quarters · filed 2026-05-06
2024-12-31$166.16M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02
$169.74M
derived: sum of 2 quarters · filed 2026-03-02
$186.57M
derived: sum of 3 quarters · filed 2026-03-02
$334.37M
10-K · filed 2026-03-02
2024-09-30$3.58M
derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-07
$20.41M
derived: sum of 2 quarters · filed 2025-11-07
$168.21M
10-Q · filed 2025-11-07
$201.49M
derived: sum of 4 quarters · filed 2026-03-02
2024-06-30$16.83M
derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06
$164.63M
10-Q · filed 2025-08-06
$197.91M
derived: sum of 3 quarters · filed 2026-03-02
$227.26M
derived: sum of 4 quarters · filed 2026-03-02
2024-03-31$147.80M
10-Q · filed 2025-05-07
$181.08M
derived: sum of 2 quarters · filed 2026-03-02
$210.43M
derived: sum of 3 quarters · filed 2026-03-02
$228.77M
derived: sum of 4 quarters · filed 2026-03-02
2023-12-31$33.28M
derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02
$62.63M
derived: sum of 2 quarters · filed 2026-03-02
$80.97M
derived: sum of 3 quarters · filed 2026-03-02
$362.02M
10-K · filed 2026-03-02
2023-09-30$29.35M
derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07
$47.69M
derived: sum of 2 quarters · filed 2024-11-07
$328.74M
10-Q · filed 2024-11-07
$340.66M
derived: sum of 4 quarters · filed 2025-02-27
2023-06-30$18.34M
derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08
$299.39M
10-Q · filed 2024-08-08
$311.31M
derived: sum of 3 quarters · filed 2025-02-27
$316.09M
derived: sum of 4 quarters · filed 2025-02-27
2023-03-31$281.05M
10-Q · filed 2024-05-02
$292.97M
derived: sum of 2 quarters · filed 2025-02-27
$297.75M
derived: sum of 3 quarters · filed 2025-02-27
2022-12-31$11.92M
derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27
$16.70M
derived: sum of 2 quarters · filed 2025-02-27
$87.26M
10-K · filed 2025-02-27
2022-09-30$4.78M
derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02
$75.34M
10-Q · filed 2023-11-02
2022-06-30$70.56M
10-Q · filed 2023-08-03
2021-12-31$19.64M
derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28
$19.64M
derived: sum of 2 quarters · filed 2024-02-28
$32.29M
derived: sum of 3 quarters · filed 2024-02-28
$48.56M
10-K · filed 2024-02-28
2021-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07
$12.65M
derived: sum of 2 quarters · filed 2022-11-07
$28.92M
10-Q · filed 2022-11-07
$28.34M
derived: sum of 4 quarters · filed 2023-03-16
2021-06-30$12.65M
derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11
$28.92M
10-Q · filed 2022-08-11
$28.34M
derived: sum of 3 quarters · filed 2023-03-16
$52.31M
derived: sum of 4 quarters · filed 2023-03-16
2021-03-31$16.26M
10-Q · filed 2022-05-09
$15.68M
derived: sum of 2 quarters · filed 2023-03-16
$39.66M
derived: sum of 3 quarters · filed 2023-03-16
$183.92M
derived: sum of 4 quarters · filed 2023-03-16
2020-12-31-$581.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16
$23.39M
derived: sum of 2 quarters · filed 2023-03-16
$167.66M
derived: sum of 3 quarters · filed 2023-03-16
$168.35M
10-K · filed 2023-03-16
2020-09-30$23.98M
derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09
$168.24M
derived: sum of 2 quarters · filed 2021-11-09
$168.93M
10-Q · filed 2021-11-09
$179.20M
derived: sum of 4 quarters · filed 2022-03-10
2020-06-30$144.26M
derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-16
$144.95M
10-Q · filed 2021-08-16
$155.22M
derived: sum of 3 quarters · filed 2022-03-10
$164.21M
derived: sum of 4 quarters · filed 2022-03-10
2020-03-31$686.00K
10-Q · filed 2021-05-10
$10.96M
derived: sum of 2 quarters · filed 2022-03-10
$19.94M
derived: sum of 3 quarters · filed 2022-03-10
2019-12-31$10.27M
derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-10
$19.26M
derived: sum of 2 quarters · filed 2022-03-10
$19.50M
10-K · filed 2022-03-10
2019-09-30$8.98M
derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05
$9.23M
10-Q · filed 2020-11-05
2019-06-30$243.00K
10-Q · filed 2020-08-06
2018-12-31$8.00K
derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-11
$9.10M
derived: sum of 2 quarters · filed 2021-03-11
$91.42M
derived: sum of 3 quarters · filed 2021-03-11
$92.97M
10-K · filed 2021-03-11
2018-09-30$9.09M
derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06
$91.41M
derived: sum of 2 quarters · filed 2019-11-06
$92.96M
10-Q · filed 2019-11-06
$94.03M
derived: sum of 4 quarters · filed 2020-03-12
2018-06-30$82.32M
derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-01
$83.87M
10-Q · filed 2019-08-01
$84.95M
derived: sum of 3 quarters · filed 2020-03-12
$84.95M
derived: sum of 4 quarters · filed 2020-03-12
2018-03-31$1.55M
10-Q · filed 2019-05-02
$2.63M
derived: sum of 2 quarters · filed 2020-03-12
$2.63M
derived: sum of 3 quarters · filed 2020-03-12
2017-12-31$1.07M
derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-12
$1.07M
derived: sum of 2 quarters · filed 2020-03-12
$1.11M
10-K · filed 2020-03-12
2017-09-30$0.00
derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-01
$37.00K
10-Q · filed 2018-11-01
2017-06-30$37.00K
10-Q · filed 2018-07-31
2016-12-31$1.17M
10-K · filed 2019-03-07
2016-06-30$1.07M
10-Q · filed 2017-08-09
2015-12-31$2.58M
10-K · filed 2018-03-16
2012-06-30$79.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03
$79.00K
10-Q · filed 2012-08-03
-$4.11M
derived: sum of 3 quarters · filed 2012-08-03
$177.00K
derived: sum of 4 quarters · filed 2012-08-03
2012-03-31$0.00
10-Q · filed 2012-05-07
-$4.19M
derived: sum of 2 quarters · filed 2012-05-07
$98.00K
derived: sum of 3 quarters · filed 2012-05-07
$242.00K
derived: sum of 4 quarters · filed 2012-08-03
2011-12-31-$4.19M
derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-07
$98.00K
derived: sum of 2 quarters · filed 2012-03-07
$242.00K
derived: sum of 3 quarters · filed 2012-08-03
$386.00K
10-K · filed 2012-03-07
2011-09-30$4.29M
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03
$4.43M
derived: sum of 2 quarters · filed 2012-08-03
$4.58M
10-Q · filed 2011-11-03
$98.46M
derived: sum of 4 quarters · filed 2012-08-03
2011-06-30$144.00K
derived: 10-Q 6 month − 10-Q 3 month · filed 2012-08-03
$288.00K
10-Q · filed 2012-08-03
$94.18M
derived: sum of 3 quarters · filed 2012-08-03
$94.21M
derived: sum of 4 quarters · filed 2012-08-03
2011-03-31$144.00K
10-Q · filed 2012-05-07
$94.03M
derived: sum of 2 quarters · filed 2012-05-07
$94.07M
derived: sum of 3 quarters · filed 2012-05-07
2010-12-31$93.89M
derived: 10-K 12 month − 10-Q 9 month · filed 2012-03-07
$93.92M
derived: sum of 2 quarters · filed 2012-03-07
$104.11M
10-K · filed 2012-03-07
2010-09-30$37.00K
derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-03
$10.23M
10-Q · filed 2011-11-03
2010-06-30$10.19M
10-Q · filed 2011-08-05
2009-12-31$51.63M
10-K · filed 2012-03-07

Similar stocks

Stock NameCountryMarket CapPE Ratio
Aclaris Therapeutics, Inc. (ACRS)United States$0.792B-9.78
Olema Pharmaceuticals, Inc. (OLMA)United States$0.790B-5.35
GYRE THERAPEUTICS, INC. (GYRE)United States$0.818B-24.71
LEXICON PHARMACEUTICALS, INC. (LXRX)United States$0.823B-17.48
Wave Life Sciences, Inc. (WVE)$0.780B-5.56
Obsidian Therapeutics, Inc. (OBX)United States$0.829B
Immix Biopharma, Inc. (IMMX)United States$0.837B-18.44
Design Therapeutics, Inc. (DSGN)United States$0.766B-12.78
Avalo Therapeutics, Inc. (AVTX)United States$0.842B-9.74
Faeth Therapeutics, Inc. (FTH)United States$0.750B